Avacopan is superior to prednisone taper in preventing relapse in patients with antineutrophil cytoplasmic antibody-associated vasculitis at 1 year, and is at least as effective as steroids in ...

Patients with ANCA-associated vasculitis are at risk for potentially lethal complications, such as glomerulonephritis, as well as organ damage from the long-term use of prednisone.

Currently, treatment for ANCA-associated vasculitis typically involves use of high doses of a glucocorticoid like prednisone to tamp down the inflammation that breaks down blood vessels.

Currently, treatment for ANCA-associated vasculitis typically involves use of high doses of a glucocorticoid like prednisone to tamp down the inflammation that breaks down blood vessels. But use ...

The trial included 330 patients with ANCA-associated vasculitis (of whom 81% had renal involvement) randomly assigned to receive avacopan (166 patients) or prednisone (164 patients).

Avacopan yielded significantly better kidney function outcomes than prednisone in a cohort of patients with renal disease associated with anti-neutrophil cytoplasmic antibody vasculitis, according ...

Findings showed that 72.3% of avacopan-treated patients achieved disease remission (as assessed by Birmingham Vasculitis Activity Score) at week 26 compared with 70.1% of prednisone-treated ...

Current therapies for ANCA-associated vasculitis and other related illnesses typically include broad immunosuppression with daily doses of glucocorticoids (steroids) such as prednisone or ...

Emerging ANCA Vasculitis therapies in the different phases of clinical trials are- MT-2990, KYV-101, Povetacicept, NM8074, Sparsentan, Abatacept, BDB-001 injection, Avacopan, Iptacopan, ALE.F02 ...